

## Review Article

# INVESTIGATING THE ROLE OF *WITHANIA SOMNIFERA* IN MANAGING UROLITHIASIS AND RELATED HEALTH CONDITIONS

Shatavant Yadav\*, Jitender Malik, Shivam Raikwar, Gyan Singh

Faculty of Pharmacy, PK University, Thanra - 473665, Madhya Pradesh, India,  
[yadavshatavant87380@gmail.com](mailto:yadavshatavant87380@gmail.com)

DOI : [doi.org/10.58924/rjams.v4.iss2.p4](https://doi.org/10.58924/rjams.v4.iss2.p4)

Received : 18 - 03 - 2025

Revised : 12 - 04 - 2025

Accepted : 24 - 04 - 2025

Publication : 28 - 04 - 2025

## Abstract;

**Background** – Urolithiasis, a condition marked by the formation of kidney stones, remains a pressing global health concern due to its high recurrence and limited treatment outcomes. While conventional therapies target symptom management, they often fail to address the underlying mechanisms of stone formation. *Withania somnifera* (Ashwagandha), a revered medicinal plant in Ayurveda, offers a promising alternative with its broad-spectrum therapeutic effects, including antioxidant, anti-inflammatory, and diuretic properties. This review explores its potential as a holistic solution for managing urolithiasis and associated health conditions.

## Methods

A systematic review was conducted to evaluate *Withania somnifera*'s phytochemical composition, pharmacological activities, and anti-urolithiatic potential. Preclinical studies were analyzed for insights into its mechanisms of action, while advanced analytical techniques such as HPLC and GC-MS were reviewed for identifying key bio actives. The role of innovative delivery systems, including Nano formulations, in enhancing efficacy was also assessed.

## Results

*Withania somnifera* exhibits a rich phytochemical profile, including withanolides, flavonoids, and alkaloids, which target critical pathways of kidney stone formation by reducing oxidative stress, inhibiting inflammation, and preventing crystal aggregation. Its nephroprotective effects extend to managing comorbidities like diabetes and hypertension. Emerging Nano formulations further enhance its bioavailability, amplifying its therapeutic potential.

## Conclusion

*Withania somnifera* represents a paradigm shift in urolithiasis management, offering a natural, multi-mechanistic approach. Future efforts should focus on clinical validation, standardization, and innovative delivery systems to unlock its full therapeutic potential.

**Key words:** Urolithiasis, *Withania somnifera*, nephroprotection, oxidative stress, anti-inflammatory

**Source of support :** Nil.

**Conflict of interest :** None

## INTRODUCTION:

Urolithiasis, sometimes known as kidney stone disease, is a common medical illness where crystalline deposits develop in the urinary tract, specifically in the kidneys. Increasing incidence associated to dietary variables, dehydration, and environmental circumstances affects millions of individuals globally [1]. The condition is often associated with severe pain, urinary tract infections, and in some cases, kidney damage. Despite various treatment options, including lithotripsy, surgical intervention, and pharmacotherapy, the recurrence rate remains high, making long-term management challenging. These limitations highlight the need for alternative treatments that can prevent recurrence and address the root causes of stone formation [2].

Given the limitations of conventional treatments, there is growing interest in exploring natural remedies for managing urolithiasis. Herbal medicine, with its historical use in addressing a variety of ailments, offers a holistic approach to treatment [3]. Plants with anti-inflammatory, antioxidant, and diuretic properties are of particular interest for urolithiasis, as they may help reduce the formation of kidney stones, prevent crystal aggregation, and promote the expulsion of stones. Natural remedies are also sought after for their fewer side effects, cost-effectiveness, and potential for long-term management without the need for invasive procedures [4].

*Withania somnifera*, commonly known as Ashwagandha, is an important herb in traditional Ayurvedic medicine. Known for its adaptogenic properties, it has been traditionally used to enhance physical and mental well-being [5]. Beyond its role in stress management, *Withania somnifera* is gaining attention for its potential to manage various health conditions, including renal disorders such as urolithiasis. The herb is rich in bioactive compounds, such as withanolides, which exhibit antioxidant, anti-inflammatory, and nephroprotective properties. Research suggests that these compounds may help address key mechanisms involved in urolithiasis, such as oxidative stress and inflammation, thereby offering a natural alternative to support kidney health and prevent stone formation [6].

## 2. Pathophysiology of Urolithiasis

### 2.1. Mechanism of Stone Formation

When urine becomes too concentrated, it starts to create kidney stones. Supersaturation happens when the concentration of several compounds beyond their solubility limitations; this includes calcium, oxalate, uric acid, and phosphate [7]. This creates an environment in which crystals begin to form. Dehydration, high dietary intake of stone-forming substances, and a low urinary volume are major contributors to this condition. Once supersaturation is established, crystal nucleation occurs, where individual ions aggregate to form a nucleus, which serves as the initial particle for further stone growth [8].

Once nucleation has occurred, the crystals begin to grow by accumulating more ions from the surrounding urine. Urinary pH, the presence of inhibitors, and the overall composition of urine play key roles in the rate of crystal growth [9]. In addition to growth, crystals may aggregate with other particles or organic material, leading to larger stone formations. These larger crystals can become trapped within the kidney or urinary tract due to reduced urine flow or the inability to expel them effectively, contributing to the persistence and recurrence of kidney stones [10].

## 2.2. Role of Oxidative Stress and Inflammation

Oxidative stress is a critical factor in the development and progression of urolithiasis. Free radicals, particularly reactive oxygen species (ROS), are generated during various metabolic processes and contribute to kidney damage by increasing oxidative stress in the renal tissues [11]. ROS induce cellular injury and disrupt the normal functioning of the kidney, making it more prone to stone formation. Furthermore, oxidative stress enhances crystal formation by modifying the properties of crystals, making them more likely to aggregate and grow [12].

In addition to oxidative stress, inflammation plays a central role in urolithiasis. The presence of kidney stones triggers an inflammatory response in the urinary tract, releasing pro-inflammatory cytokines, chemokines, and other mediators [13]. This inflammatory cascade not only damages the renal tissues but also facilitates the aggregation and retention of crystals. Chronic inflammation in the kidneys further aggravates the formation of stones by promoting cellular damage and crystal retention, thus creating a vicious cycle that accelerates the recurrence of urolithiasis [14].

**Table 1: Key Factors Contributing to Urolithiasis [15]**

Factor	Description
Dehydration	Reduced urine volume leading to supersaturation of stone-forming substances.
High Dietary Sodium	Excess sodium intake increases calcium excretion, contributing to stone formation.
High Oxalate Diet	Excess dietary oxalate can combine with calcium to form calcium oxalate stones.
Hypercalciuria	Elevated calcium levels in urine increase the risk of stone formation.
Hyperuricosuria	High uric acid levels in urine can lead to uric acid stones.
Low Urine pH	Acidic urine promotes the formation of uric acid and cystine stones.
Genetic Factors	Family history of urolithiasis can increase susceptibility to kidney stones.
Obesity	Obesity is associated with increased risk due to altered metabolic processes.
Hyperparathyroidism	Increased parathyroid hormone levels raise calcium levels in urine.
Increased Protein Intake	High animal protein intake can increase urinary calcium and uric acid.
Environmental Factors	Hot climates leading to dehydration and reduced urine output.
Medications	Certain drugs, like diuretics or antacids, can alter urine composition and promote stone formation.

## 3. Phytochemical Composition of *Withania somnifera*

### 3.1. Bioactive Compounds in *Withania somnifera*

*Withania somnifera*, also known as Ashwagandha, is a highly valued medicinal plant renowned for its diverse bioactive compounds that contribute to its therapeutic effects. The key bioactive compounds in *Withania somnifera* include withanolides, alkaloids, flavonoids, and several other phytochemicals, each playing an important role in its pharmacological activities [16].

- **Withanolides:** Withanolides, steroidal lactones, are the most significant and well-studied bioactive compounds in *Withania somnifera*. These substances have strong anti-inflammatory, anti-cancer, and antioxidant capabilities. Particularly for organs like the kidneys, their capacity to neutralise free radicals and safeguard against oxidative damage is crucial for preventing cellular damage. Withanolides also enhance cellular resilience by regulating stress hormones and supporting immune function, offering protective benefits for kidney health, especially in conditions like urolithiasis [17].
- **Alkaloids:** Alkaloids such as withanine and somniferine are another important group of compounds in *Withania somnifera*. These alkaloids have been linked to various health benefits, including neuroprotective

and immunomodulatory effects. By influencing central nervous system functions and promoting metabolic balance, they may help manage the stress response, reducing the overall burden on the body's physiological systems, including the renal system [18].

- **Flavonoids:** The anti-inflammatory and antioxidant properties of flavonoids are well-known. An important function of flavonoids in *Withania somnifera* is to protect renal tissues from oxidative stress, a major factor in the formation of kidney stones and kidney damage. They contribute to the reduction of inflammation and help in detoxification, thus supporting kidney health and preventing the recurrence of conditions like urolithiasis [19].

### 3.2. Pharmacological Properties

The bioactive compounds found in *Withania somnifera* contribute to several pharmacological properties that are highly beneficial for kidney health. Among these, its antioxidant, anti-inflammatory, and diuretic activities are particularly relevant [20].

- **Antioxidant Activity:** The presence of withanolides and flavonoids gives *Withania somnifera* its powerful antioxidant capabilities. These chemicals aid in free radical neutralisation, which lowers kidney oxidative stress and protects cells from damage that might cause urolithiasis [21].
- **Anti-inflammatory Activity:** Chronic inflammation is a significant factor in the progression of kidney stones and related conditions. The anti-inflammatory compounds in *Withania somnifera*, particularly withanolides, help inhibit the release of pro-inflammatory cytokines and reduce inflammation, supporting renal health and preventing damage [22].
- **Diuretic Activity:** *Withania somnifera* also exhibits diuretic properties, which promote the elimination of excess waste products and prevent the formation of stones by increasing urine flow. This can be beneficial in the prevention and management of urolithiasis by helping flush out stone-forming minerals from the urinary system [23].

**Table 2: Phytochemical Composition and Associated Therapeutic Activities of *Withania somnifera* [24]**

Phytochemical	Description	Therapeutic Activity
Withanolides	Steroidal lactones, the primary bioactive compounds in Ashwagandha.	Antioxidant, anti-inflammatory, anticancer, adaptogenic, and nephroprotective properties.
Alkaloids	Includes compounds like withanine and somniferine.	Neuroprotective, immunomodulatory, and stress-reducing activities.
Flavonoids	Plant-derived polyphenolic compounds with antioxidant properties.	Antioxidant, anti-inflammatory, and anti-urolithiasis effects.
Saponins	Glycosides found in <i>Withania somnifera</i> , contributing to its therapeutic effects.	Antimicrobial, anti-inflammatory, and adaptogenic properties.
Triterpenoids	Includes compounds like withasferol and sitoindosides.	Anti-inflammatory, anti-cancer, and hepatoprotective activities.
Phenolic Acids	Includes rosmarinic acid and other phenolics.	Antioxidant, anti-inflammatory, and kidney-protective properties.
Lipids	Fatty acids and glycerides present in the plant.	Antioxidant, anti-inflammatory, and skin health benefits.
Vitamins (e.g., Vitamin C)	Vital micronutrients with antioxidant roles.	Boosts immune system, reduces oxidative stress, and supports renal health.
Tannins	Polyphenolic compounds with astringent properties.	Antioxidant, anti-inflammatory, and anti-microbial activities.
Essential Oils	Volatile oils with various bioactive properties.	Antimicrobial, anti-inflammatory, and stress-

		relieving effects.
Proteins and Peptides	Includes various proteins with biological activity.	Immunomodulatory and wound healing properties.
Carbohydrates	Simple sugars, oligosaccharides, and polysaccharides.	Support immune health, energy metabolism, and cell regeneration.

#### 4. Role of *Withania somnifera* in Managing Urolithiasis

##### 4.1. Preclinical Evidence

Preclinical studies conducted on animal models have provided compelling evidence regarding the anti-urolithiatic effects of *Withania somnifera*. In these studies, various animal models of urolithiasis, induced by methods like calcium oxalate crystal formation, were treated with extracts from *Withania somnifera*. Results have shown significant reductions in stone formation, both in terms of the size and number of stones [25]. In some cases, *Withania somnifera* has also demonstrated its potential to aid in the dissolution of already-formed stones. The bioactive compounds, including withanolides, alkaloids, and flavonoids, are considered pivotal in mediating these effects by acting on the key pathological mechanisms involved in stone formation, such as oxidative stress and inflammation. These studies highlight the potential of *Withania somnifera* as a promising therapeutic option in the prevention and management of urolithiasis [26].

##### 4.2. Mechanisms of Action

The therapeutic effects of *Withania somnifera* in managing urolithiasis are attributed to its multifaceted mechanisms of action, primarily involving its antioxidant, anti-inflammatory, and diuretic properties [27].

- **Antioxidant Activity:** *Withania somnifera* is well-known for its potent antioxidant activity, which plays a crucial role in mitigating the oxidative stress that is often involved in kidney stone formation. The antioxidant compounds, particularly withanolides, work by scavenging free radicals and reducing reactive oxygen species (ROS) that can damage renal cells. This protective effect helps to maintain kidney health and prevent further stone formation by reducing oxidative damage to kidney tissues [28].
- **Anti-inflammatory Effects:** One of the main causes of urolithiasis is chronic inflammation. The anti-inflammatory actions of *Withania somnifera* are achieved through regulating the expression of cytokines and mediators that promote inflammation, including TNF- $\alpha$ , IL-6, and COX-2. By reducing inflammation, it helps alleviate the kidney damage associated with stone formation and prevents the development of additional stones [29].




Figure 1: Mechanistic diagram of *Withania somnifera*'s role in managing



## urolithiasis [31]

- **Diuretic Properties:** Another key mechanism through which *Withania somnifera* aids in managing urolithiasis is its diuretic effect. By promoting increased urine output, *Withania somnifera* helps to flush out excess calcium and other stone-forming minerals from the renal system. This diuretic activity reduces the concentration of crystals in the urine and aids in the expulsion of small stones, helping prevent their accumulation and formation in the kidneys [30].

## 5. Role in Managing Related Health Conditions

### 5.1. Nephroprotective Effects

*Withania somnifera* has demonstrated significant nephroprotective properties, making it a valuable herb in managing kidney health. Kidney damage, often caused by oxidative stress, is a key contributor to various renal diseases, including urolithiasis [32]. *Withania somnifera*, through its antioxidant-rich phytochemical profile, helps counteract oxidative damage in kidney cells. The bioactive compounds, especially withanolides, have shown the ability to reduce the levels of reactive oxygen species (ROS), thereby protecting renal tissues from oxidative injury [33]. In conditions like chronic kidney disease (CKD) or those exacerbated by the presence of kidney stones, *Withania somnifera* helps maintain kidney function by mitigating oxidative stress, reducing inflammation, and preventing fibrosis, ensuring better renal health and preventing further damage [34].

### 5.2. Anti-Inflammatory Benefits

The anti-inflammatory effects of *Withania somnifera* play a crucial role not only in urolithiasis management but also in alleviating conditions often seen as comorbidities, such as diabetes and hypertension. Chronic inflammation is a common underlying factor in both these conditions, which can contribute to the progression of kidney damage and worsen urolithiasis [35]. *Withania somnifera* helps modulate the inflammatory response by downregulating the production of pro-inflammatory cytokines and mediators, including TNF- $\alpha$ , IL-6, and COX-2. By reducing systemic inflammation, *Withania somnifera* assists in managing comorbidities, thereby reducing the risk of kidney damage and improving overall health outcomes in individuals suffering from diabetes and hypertension [36].

### 5.3. Immunomodulatory Properties

Beyond its anti-inflammatory and nephroprotective effects, *Withania somnifera* is recognized for its immunomodulatory properties, enhancing the body's immune response. In states of chronic illness, such as kidney disease or diabetes, the immune system may become compromised, leading to increased susceptibility to infections and a diminished ability to repair damaged tissues [37]. *Withania somnifera* helps to regulate immune function, supporting both innate and adaptive immune responses. This is particularly beneficial in conditions like urolithiasis, where infections or inflammation can further aggravate kidney damage. By boosting the immune system, *Withania somnifera* contributes to overall health, enhancing the body's ability to combat pathogens, repair tissues, and maintain systemic equilibrium [38,39].

## 6. Challenges and Future Perspectives

### 6.1. Current Research Limitations

While the preclinical evidence for *Withania somnifera* in the management of urolithiasis is promising, there are several limitations in the current body of research that hinder its widespread application. One of the most significant challenges is the lack of large-scale clinical trials [40]. Most studies have been conducted on animal models or small human sample sizes, making it difficult to draw definitive conclusions regarding its efficacy, safety, and optimal dosages for human use. Furthermore, the variability in the preparation and dosage forms of *Withania somnifera* adds another layer of complexity [41]. Different extraction methods, formulations, and dosages have been used across studies, leading to inconsistent results. The standardization of dosage forms and the development of robust clinical trial data are essential to validate its potential as an effective therapeutic for urolithiasis and related conditions [42].

## 6.2. Future Directions

Future research on *Withania somnifera* holds significant promise, particularly with the potential for standardized formulations. To maximize its therapeutic efficacy, it is crucial to develop uniform and well-defined preparations of *Withania somnifera*, ensuring consistency in dosage and bioavailability [43]. Advances in pharmaceutical technology, including novel drug delivery systems like nanoparticles and liposomes, could further enhance the bioactivity of its key compounds. In addition, integrating *Withania somnifera* into mainstream treatment protocols for urolithiasis could be a potential future direction. Its combination with conventional treatments might provide a synergistic effect, offering better management of kidney stones, reducing recurrence rates, and improving overall kidney health [44]. Collaborative efforts between pharmacologists, clinicians, and researchers will be crucial in overcoming existing barriers and translating the therapeutic potential of *Withania somnifera* into practical, clinically applicable solutions [45].

## 7. Conclusion

*Withania somnifera* has demonstrated substantial potential in managing urolithiasis, owing to its multifaceted therapeutic properties, including antioxidant, anti-inflammatory, and diuretic effects. The plant's bioactive compounds, such as withanolides, alkaloids, and flavonoids, offer a promising approach for preventing and treating kidney stones while supporting overall kidney health. In addition to its role in urolithiasis management, *Withania somnifera* has shown efficacy in managing related conditions like hypertension, diabetes, and kidney damage through its nephroprotective, anti-inflammatory, and immunomodulatory effects. However, despite the promising preclinical evidence and traditional use, the current body of research is limited by the lack of large-scale clinical trials and variability in the formulation and dosage forms used. To fully harness the therapeutic potential of *Withania somnifera*, it is crucial to conduct comprehensive clinical studies that will establish standardized formulations and optimal dosing guidelines. This will help translate its benefits into more reliable and effective treatment options for urolithiasis and related health conditions. In conclusion, while *Withania somnifera* holds great promise as a natural adjunct in urolithiasis management, further research is needed to confirm its clinical efficacy and integrate it into mainstream treatment protocols. With continued exploration and development, *Withania somnifera* may emerge as a valuable tool in managing kidney health and preventing the recurrence of kidney stones.

## REFERENCES

1. Wang Z, Zhang Y, Zhang J, Deng Q, Liang H. Recent advances on the mechanisms of kidney stone formation. *International journal of molecular medicine*. 2021 Aug 1;48(2):1-0.
2. Riella C, Czarnecki PG, Steinman TI. Renal Complications: Pain, Infection, and Nephrolithiasis. *Polycystic Kidney Disease: Translating Mechanisms into Therapy*. 2018:155-69.
3. Butterweck V, Khan SR. Herbal medicines in the management of urolithiasis: alternative or complementary? *Planta medica*. 2009 Aug;75(10):1095-103.
4. Ahmed S, Hasan MM, Mahmood ZA. Globally used antiurolithiatic plants of family Asteraceae: Historical background, mechanism of action, therapeutic spectrum, formulations with doses. *Journal of Pharmacognosy and Phytochemistry*. 2017;6(3):394-402.
5. Mukherjee PK, Banerjee S, Biswas S, Das B, Kar A, Katiyar CK. *Withania somnifera* (L.) Dunal-Modern perspectives of an ancient Rasayana from Ayurveda. *Journal of ethnopharmacology*. 2021 Jan 10;264:113157.
6. Manikandaselvi S, Vadivel V, Brindha P. Nutraceuticals–An overview. *Int J Pharm Bio Sci*. 2016 Jan;7(1):284-96.
7. Kavanagh JP. Physicochemical aspects of uro-crystallization and stone formation. In *Urinary Tract Stone Disease 2010 Dec 2* (pp. 17-30). London: Springer London.
8. Sohga A, Bigoniya P. A review on epidemiology and etiology of renal stone. *Am J Drug Discov Dev*. 2017 Mar 15;7(2):54-62.
9. Dent CE, Sutor DJ. Presence or absence of inhibitor of calcium-oxalate crystal growth in urine of normals and of stone-formers. *The Lancet*. 1971 Oct 9;298(7728):775-8.
10. Mohankumar A, Ganesh R, Shanmugam P. Exploring the Connection Between Bacterial Biofilms and Renal Calculi: A Comprehensive Review. *Journal of Pure & Applied Microbiology*. 2024 Dec 1;18(4).
11. Boonla C. Oxidative stress in urolithiasis. *Reactive Oxygen Species (ROS) in Living Cells*. 2018 May 23:129-59.
12. Khan SR. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. *The Journal of urology*. 2013 Mar;189(3):803-11.
13. Wigner P, Grębowski R, Bijak M, Szemraj J, Saluk-Bijak J. The molecular aspect of nephrolithiasis development. *Cells*. 2021 Jul 29;10(8):1926.
14. Franklin BS, Mangan MS, Latz E. Crystal formation in inflammation.



Annual review of immunology. 2016 May 20;34(1):173-202.

15. Wróbel G, Kuder T. The role of selected environmental factors and the type of work performed on the development of urolithiasis—a review paper. *International Journal of Occupational Medicine and Environmental Health*. 2019 Oct 16;32(6):761-75.
16. Namdeo AG, Ingawale DK. Ashwagandha: Advances in plant biotechnological approaches for propagation and production of bioactive compounds. *Journal of Ethnopharmacology*. 2021 May 10;271:113709.
17. Bhat JA, Akther T, Najar RA, Rasool F, Hamid A. Withania somnifera (L.) Dunal (Ashwagandha); current understanding and future prospect as a potential drug candidate. *Frontiers in Pharmacology*. 2022 Dec 12;13:1029123.
18. Bashir A, Nabi M, Tabassum N, Afzal S, Ayoub M. An updated review on phytochemistry and molecular targets of Withania somnifera (L.) Dunal (Ashwagandha). *Frontiers in Pharmacology*. 2023 Mar 29;14:1049334.
19. Dar NJ, Hamid A, Ahmad M. Pharmacologic overview of Withania somnifera, the Indian Ginseng. *Cellular and molecular life sciences*. 2015 Dec;72:4445-60.
20. Jeyanthi T, Subramanian P. Nephroprotective effect of Withania somnifera: a dose-dependent study. *Renal failure*. 2009 Oct 1;31(9):814-21.
21. Sun GY, Li R, Cui J, Hannink M, Gu Z, Fritsche KL, Lubahn DB, Simonyi A. Withania somnifera and its withanolides attenuate oxidative and inflammatory responses and up-regulate antioxidant responses in BV-2 microglial cells. *Neuromolecular medicine*. 2016 Sep;18:241-52.
22. B. Aggarwal B, Prasad S, Reuter S, Kannappan R, R. Yadav V, Park B, Hye Kim J, C. Gupta S, Phromnoi K, Sundaram C, Prasad S. Identification of novel anti-inflammatory agents from Ayurvedic medicine for prevention of chronic diseases: “reverse pharmacology” and “bedside to bench” approach. *Current drug targets*. 2011 Oct 1;12(11):1595-653.
23. Maharana L, Dadhich OP. Review on role of Herbal Drug in Prevention and Management of Kidney Stone. *Journal of Ayurveda*. 2015 Apr;9(2).
24. A. Dar P, R. Singh L, A. Kamal M, A. Dar T. Unique medicinal properties of Withania somnifera: Phytochemical constituents and protein component. *Current pharmaceutical design*. 2016 Feb 1;22(5):535-40.
25. Makbul SA, Jahan N, Kalam MA. Bio-active compounds from unani medicinal plants and their application in urolithiasis. *Natural Bio-active Compounds: Volume 2: Chemistry, Pharmacology and Health Care Practices*. 2019:369-407.

26. Logie E, Vanden Berghe W. Tackling chronic inflammation with withanolide phytochemicals—A withaferin a perspective. *Antioxidants*. 2020 Nov 10;9(11):1107.
27. Murugan SP, Murugesan K, Muthusamy Y, Basalingappa KM, Murugan M, Mahendran N, Rajendran P, Kuppannan G, Arthanari M. The Role of Bioactive Principles from Traditional Medicinal Plants in Metabolic Disorder. *Plant Derived Bioactive Compounds in Human Health and Disease*. 2025:8-32.
28. Noh S, Go A, Kim DB, Park M, Jeon HW, Kim B. Role of antioxidant natural products in management of infertility: a review of their medicinal potential. *Antioxidants*. 2020 Oct 7;9(10):957.
29. Yattoo MI, Gopalakrishnan A, Saxena A, Parray OR, Tufani NA, Chakraborty S, Tiwari R, Dhama K, Iqbal HM. Anti-inflammatory drugs and herbs with special emphasis on herbal medicines for countering inflammatory diseases and disorders-a review. *Recent patents on inflammation & allergy drug discovery*. 2018 May 1;12(1):39-58.
30. Yadav A, Das R, Mehta DK, Yatin. Benefaction of Herbals in the Management of Urolithiasis. *Current Traditional Medicine*. 2021 Aug 1;7(4):541-51.
31. Devhare L, Prasad C. Prophylactic and curative activity of *Withania somnifera* on experimentally induced calcium oxalate nephrolithiasis. *Journal of medical pharmaceutical and allied sciences*. 2024;13(4):6687-95.
32. Basist P, Parveen B, Zahiruddin S, Gautam G, Parveen R, Khan MA, Krishnan A, Shahid M, Ahmad S. Potential nephroprotective phytochemicals: Mechanism and future prospects. *Journal of ethnopharmacology*. 2022 Jan 30;283:114743.
33. White PT, Subramanian C, Motiwala HF, Cohen MS. Natural withanolides in the treatment of chronic diseases. *Anti-inflammatory nutraceuticals and chronic diseases*. 2016:329-73.
34. Laasya TS, Thakur S, Poduri R, Joshi G. Current insights toward kidney injury: Decrypting the dual role and mechanism involved of herbal drugs in inducing kidney injury and its treatment. *Current Research in Biotechnology*. 2020 Nov 1;2:161-75.
35. Kapare HS, Chitlange SS, Aher KS, Nagore DH. CHRONIC KIDNEY DISEASES: AN OVERVIEW OF MANAGEMENT AND TREATMENT STRATEGIES. *Indian Drugs*. 2022 Aug 1;59(8).
36. Devkar ST, Kandhare AD, Zanzwar AA, Jagtap SD, Katyare SS, Bodhankar SL, Hegde MV. Hepatoprotective effect of withanolide-rich fraction in acetaminophen-intoxicated rat: decisive role of TNF- $\alpha$ , IL-1 $\beta$ , COX-II and iNOS. *Pharmaceutical Biology*. 2016 Nov 1;54(11):2394-403.
37. Kaur P, Makanjuola VO, Arora R, Singh B, Arora S. Immunopotentiating significance of conventionally used plant

- adaptogens as modulators in biochemical and molecular signalling pathways in cell mediated processes. *Biomedicine & Pharmacotherapy*. 2017 Nov 1;95:1815-29.
38. Sachin S, Kumar V, Sharma M, Vaishnavi V, Chaudhary P, Singh S, Sudhakar K, Kumar B, Pandey NK, Singh SK, Choudhary K. Concept and role of immunomodulatory medicinal plants used in Ayurvedic health care system. *Trends in Immunotherapy*. 2024 Aug 24;8(2).
39. Wiciński M, Fajkiel-Madajczyk A, Kurant Z, Liss S, Szyperski P, Szambelan M, Gromadzki B, Rupniak I, Słupski M, Sadowska-Krawczenko I. Ashwagandha's Multifaceted Effects on Human Health: Impact on Vascular Endothelium, Inflammation, Lipid Metabolism, and Cardiovascular Outcomes—A Review. *Nutrients*. 2024 Jul 31;16(15):2481.
40. Adhikari A, Bhattacharya S, Bose S, Ray M, Indu R, Banerjee S. Prospective experimental studies of some herbs used in urinary disorders in Unani medicine. *Advances in Traditional Medicine*. 2023 Sep;23(3):753-75.
41. McGonigle P, Ruggeri B. Animal models of human disease: challenges in enabling translation. *Biochemical pharmacology*. 2014 Jan 1;87(1):162-71.
42. Gao Y, Gesenberg C, Zheng W. Oral formulations for preclinical studies: principle, design, and development considerations. In *Developing solid oral dosage forms* 2017 Jan 1 (pp. 455-495). Academic Press.
43. Kour J, Chopra H, Bukhari S, Sharma R, Bansal R, Hans M, Saxena DC. Nutraceutical-A deep and profound concept. In *Nutraceuticals and Health Care* 2022 Jan 1 (pp. 1-28). Academic Press.

44. Kashyap VK, Peasah-Darkwah G, Dhasmana A, Jaggi M, Yallapu MM, Chauhan SC. *Withania somnifera*: progress towards a pharmaceutical agent for immunomodulation and cancer therapeutics. *Pharmaceutics*. 2022 Mar 10;14(3):611.
45. Chunarkar-Patil P, Kaleem M, Mishra R, Ray S, Ahmad A, Verma D, Bhayye S, Dubey R, Singh HN, Kumar S. Anticancer Drug Discovery based on Natural products: from computational approaches to Clinical studies. *Biomedicines*. 2024 Jan 16;12(1):201.

**How to cite this article:** Yadav S, Malik J, Raikwar S, Singh G. Investigating the role of *Withania somnifera* in managing urolithiasis and related health conditions. *Research Journal of Applied Medical Sciences* ,2025;4(2):43-54

Copyright © 2025 The Author(s): This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 (CC BY-NC 4.0) International License.